Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sounds great Diogenes--->>> FIRE & FLOWER ANNOUNCES FILING OF FORM 40-F WITH SEC AS COMPANY PREPARES FOR NASDAQ LISTING
JANUARY, 19, 2022
THE VALENS COMPANY REVIEWS 2021 MILESTONES & ANNOUNCES VIRTUAL INVESTOR DAY
The Valens Company to host virtual Investor Day on February 7, 2022
KELOWNA, BC, Jan. 18, 2022 /PRNewswire/ – The Valens Company Inc. (TSX: VLNS) (NASDAQ: VLNS) (the “Company” “The Valens Company” or “Valens”), a leading manufacturer of cannabis products, is pleased to provide a summary of key milestones and achievements made by the Company in 2021.
The Company is also pleased to announce it will hold a virtual investor day on February 7, 2022 at 11:00 AM ET. Valens executive management team will discuss 2022 corporate initiatives including recent developments, financial objectives, acquisition updates, and will provide insights into the Company’s operations. The Company will send out more information to analysts and investors closer to the date for anyone who is interested in attending the virtual event.
“We recognize 2021 was an especially tough year for cannabis and small-cap growth investors. This is top of mind for Valens management as we too are committed shareholders of Valens,” said Tyler Robson, Chief Executive Officer and Chair of The Valens Company. “In addition to the overall industry and economic challenges of 2021, supply-chain issues disrupted the flow of goods across the world. We nevertheless worked to increase operational efficiencies and succeeded in accelerating our business plan, expanding our presence into the world of branded products and finished-goods manufacturing. We are now very well-positioned to drive revenue growth in 2022, drive further cost efficiencies following a very acquisitive 2021, go after targeted marketing opportunities, and become a competitive force globally. Looking to the future, we continue to believe in the significant potential of the cannabis industry, and we are now more excited than ever by the long-term opportunity for The Valens Company shareholders.”
The Valens Company’s 2021 Milestones:
Sales & Corporate Achievements:
Successfully transitioned the business model from toll processing to finished product manufacturing to branded product sales in 18 months
As of Q3 2021, product sales including both provincial sales and B2B sales of finished goods represented 93.0% of revenue up from 48.0% in Q1 2020
Higher-margin B2C segment represented 49.0% of revenue in Q3 2021 up from 25.0% in Q1 2021 and Valens expects B2C to be 75% to 85% of revenue in 2022 after the Citizen Stash acquisition
One of the fastest growing LPs in Canada, with robust provincial listings’ growth of 141% from Q1 2021 to Q3 2021, 181 Canada-wide provincial listings by the end of Q3, and a total of 248 subsequent to quarter end (including 27 new approvals and the 40 provincial listings held by Citizen Stash)
Aggregate consumption-level retail sales increased 76.5% in Q3 2021 compared to Q2 2021 based on Hifyre data for Alberta, Ontario, and British Columbia
Optimized B2B operations to align with the fewer, bigger, better promise with the addition and expansion of seven manufacturing partnerships including three of the top seven Canadian licensed producers by market share, reducing working capital risks
Product & Brand Achievements:
Verse BC God Bud 28g became a top 5 best-selling SKU in the flower category in Alberta, Ontario, and British Columbia during the Q4 2021 period from September to November, and was the 2nd ranked best-selling SKU across all categories in Alberta, Ontario, and British Columbia during December 2021 according to Hifyre after only 7 months in market
Increased cannabis-infused beverage market share from 5.5% in Q1 2021 to 10.0% in Q4 2021 in Alberta, Ontario, and British Columbia, ranking 3rd in the category among all licensed producers according to Hifyre, before being able to reap the benefits of the Pommies beverage facility which was licensed in late November 2021
Ranked 6th amongst all licensed producers in the vape category by market share in Alberta, Ontario, and British Columbia during Q4 2021 based on Hifyre data not including any B2B LP sales activities in the category
Ranked 10th amongst all licensed producers in the edibles category by market share in Alberta, Ontario, and British Columbia during Q4 2021 based on Hifyre data not including any B2B LP sales activities in the category
Operational Achievements:
Successfully commissioned the K2 facility, enabling Valens to fully leverage its low-cost cannabis platform to drive product sales, accelerate entry into new innovative product verticals and increase output volumes
Launched flower, pre-rolls, and topicals as new product verticals in 2021
Doubled vape manufacturing capacity in 2021
Installed pre-roll manufacturing equipment in May 2021 at our Kelowna facility, producing 3.2 million pre-rolls in 2021 with a capacity to produce 8.6 million pre-rolls annually
Installed Nitrotin packing line, with a capacity to produce 720,000 units of 3.5g premium flower offering
Successfully commissioned the Pommies facility, providing Valens with an additional 30,000 square feet of licensed production and manufacturing space to execute on its cannabis-infused beverage commercialization and distribution strategy. Pommies can produce more than 8 million units per year on a single shift, and can produce cannabis-infused beverages in both cans and PET bottles across various sizes and formats
Acquisitions:
Successfully completed four strategic acquisitions, expanding domestic and global distribution reach with products available in eight provinces and territories, 50 states, and 10 countries. Through these acquisitions Valens has increased the total addressable market by leveraging leading brands in all respective cannabis categories
Expanded edible product capabilities through the acquisition of LYF Food Technologies Inc. Post-acquisition, Valens has brought to market innovative edible products using natural ingredients such as Double Chocolate Brownie, Toffee Crunch Milk Chocolate Bites, Peanut Butter Cups, and Very Cherry Soft Chews
Entered the US with the acquisition of Green Roads, a top 10 CBD brand by market share(1) with distribution across over 7,000 retail locations, a robust DTC e-commerce platform, over 30,000 five-star reviews, and products available in 10 countries
Strategic expansion into premium flower-based categories with the acquisition of Citizen Stash. Valens now has access to an industry leading catalogue of genetics, and contract grow relationships to quickly expand consumer offerings
Entered the value segment through the acquisition of Verse Cannabis offering a wide selection of high-quality products, providing consumers an array of cannabis consumption experiences without the uncomfortably high price point
Capital Stewardship:
Maintained the highest cannabis revenue per dollar invested amongst Canadian cannabis peers by investing in the right assets and opportunities to create long-term shareholder value
NASDAQ Listing:
As part of our capital markets strategy the Nasdaq listing positioning Valens and its shareholders for greater access to liquidity, increased corporate visibility, and a broader shareholder base in 2022
“On behalf of the executive team and board of directors, we would like to thank our shareholders, customers, and consumers for their continued support,” said Tyler Robson, Chief Executive Officer and Chair of The Valens Company “I’m exceptionally proud to say that we have achieved so many milestones that we set for 2021 including expanding our domestic distribution network, entering the US CBD market and becoming a leading B2C consumer products company with five leading brands in targeted categories, from zero at the beginning of the year.
Mr. Robson noted that, “The acquisitions we made in 2021 were targeted at achieving specific strategic objectives and are expected to demonstrate their significance for the company as we move through 2022.
These acquisitions are expected to play a key role in gaining operational efficiencies and achieving margin expansion as we increase our focus in these areas and strive to unlock their significant value for our shareholders. Furthermore, we plan to continue to build on our manufacturing partnerships, while strategically deploying capital resources to bolster our manufacturing platform and execute on our growth strategy in Canada as well as the United States. Moving into 2022, our capital markets strategy will be focused on increasing institutional and public investor outreach to strengthen our long-term relationship with our valued investor community.”
At Valens, it’s Personal.
Sources:
(1) Based on estimates from Brightfield for latest quarterly period (Q3 2021)
B2C segment includes Green Roads & Provincial Sales
About The Valens Company
The Valens Company is a leading manufacturer of cannabis products with a mission to bring the benefits of cannabis to the world. The Company provides proprietary cannabis processing services, in addition to best-in-class product development, manufacturing, and commercialization of cannabis consumer packaged goods. The Valens Company’s high-quality products are formulated for the medical, health and wellness, and recreational consumer segments, and are offered across all cannabis product categories with a focus on quality and innovation. The Company also manufactures, distributes, and sells a wide range of CBD products in the United States through its subsidiary Green Roads, and distributes medicinal cannabis products to Australia through its subsidiary Valens Australia. In partnership with brand houses, consumer packaged goods companies and licensed cannabis producers around the globe, the Company continues to grow its diverse product portfolio in alignment with evolving cannabis consumer preferences in key markets. Through Valens Labs, the Company is setting the standard in cannabis testing and research and development with Canada’s only ISO17025 accredited analytical services lab, named The Centre of Excellence in Plant-Based Science by partner and scientific world leader Thermo Fisher Scientific. Discover more on The Valens Company at http://www.thevalenscompany.com.
Notice regarding Forward Looking Statements
All information included in this press release, including any information as to the future financial or operating performance and other statements of The Valens Company that express management’s expectations or estimates of future performance, other than statements of historical fact, constitute forward-looking information or forward-looking statements within the meaning of applicable securities laws and are based on expectations, estimates and projections as of the date hereof. Forward-looking statements are included for the purpose of providing information about management’s current expectations and plans relating to the future. Wherever possible, words such as “plans”, “expects”, “scheduled”, “trends”, “forecasts”, “future”, “indications”, “potential”, “estimates”, “predicts”, “anticipate”, “to establish”, “believe”, “intend”, “ability to”, or statements that certain actions, events or results “may”, “should”, “could”, “would”, “might”, “will”, or are “likely” to be taken, occur or be achieved, or the negative of these words or other variations thereof, have been used to identify such forward-looking information. Specific forward-looking statements include, without limitation, all disclosure regarding future results of operations, future outcomes of transactions, economic conditions, and anticipated courses of action. Investors and other parties are advised that there is not necessarily any correlation between the number of SKUs manufactured and shipped and revenue and profit, and undue reliance should not be placed on such information.
The risks and uncertainties that may affect forward-looking statements include, among others, Canadian regulatory risk, Australian regulatory risk, U.S. regulatory risk, U.S. border crossing and travel bans, the uncertainties, effects of and responses to the COVID-19 pandemic, reliance on licenses, expansion of facilities, competition, dependence on supply of cannabis and reliance on other key inputs, dependence on senior management and key personnel, general business risk and liability, regulation of the cannabis industry, change in laws, regulations and guidelines, compliance with laws, limited operating history, vulnerability to rising energy costs, unfavourable publicity or consumer perception, product liability, risks related to intellectual property, product recalls, difficulties with forecasts, management of growth and litigation, many of which are beyond the control of The Valens Company. For a more comprehensive discussion of the risks faced by The Valens Company, and which may cause the actual financial results, performance or achievements of The Valens Company to be materially different from estimated future results, performance or achievements expressed or implied by forward-looking information or forward-looking statements, please refer to The Valens Company’s latest Annual Information Form filed with Canadian securities regulatory authorities at www.sedar.com or on The Valens Company’s website at www.thevalenscompany.com. The risks described in such Annual Information Form are hereby incorporated by reference herein. Although the forward-looking statements contained herein reflect management’s current beliefs and reasonable assumptions based upon information available to management as of the date hereof, The Valens Company cannot be certain that actual results will be consistent with such forward-looking information. The Valens Company cautions you not to place undue reliance upon any such forward-looking statements. The Valens Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law. Nothing herein should be construed as either an offer to sell or a solicitation to buy or sell securities of The Valens Company.
SOURCE The Valens Company Inc.
ABOUT THE VALENS COMPANY
The Valens Company is a global leader in the end-to-end development and manufacturing of innovative, cannabinoid-based products. The Valens Company is focused on being the partner of choice for leading Canadian and international cannabis brands by providing best-in-class, proprietary services including CO2, ethanol, hydrocarbon, solvent-less and terpene extraction, analytical testing, formulation and product development and custom manufacturing. Valens is the largest third-party extraction company in Canada with an annual capacity of 425,000 kg of dried cannabis and hemp biomass at our purpose-built facility in Kelowna, British Columbia which is in the process of becoming European Union (EU) Good Manufacturing Practices (GMP) compliant. The Valens Company currently offers a wide range of product formats, including tinctures, two-piece caps, soft gels, oral sprays and vape pens as well as beverages, concentrates, topicals, edibles, injectables, natural health products and has a strong pipeline of next-generation products in development for future release. Finally, The Valens Company’s wholly-owned subsidiary Valens Labs is a Health Canada licensed ISO 17025 accredited cannabis testing lab providing sector-leading analytical services and has partnered with Thermo Fisher Scientific to develop a Centre of Excellence in Plant-Based Science. For more information, please visit https://thevalenscompany.com. The Valens Company’s investor deck can be found specifically at https://thevalenscompany.com/investors/.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Jeff Fallows
The Valens Company
Investor Relations
ir@thevalenscompany.com
1 647.956.8254
KCSA Strategic Communications
Phil Carlson / Elizabeth Barker
VLNS@kcsa.com
1 212.896.1233 / 1 212.896.1203
Media
KCSA Strategic Communications
Anne Donohoe
adonohoe@kcsa.com
1 212.896.1265
NOTICE REGARDING FORWARD LOOKING STATEMENTS
All information included in this press release, including any information as to the future financial or operating performance and other statements of The Valens Company that express management’s expectations or estimates of future performance, other than statements of historical fact, constitute forward-looking information or forward-looking statements within the meaning of applicable securities laws and are based on expectations, estimates and projections as of the date hereof. Forward-looking statements are included for the purpose of providing information about management’s current expectations and plans relating to the future. Wherever possible, words such as “plans”, “expects”, “scheduled”, “trends”, “indications”, “potential”, “estimates”, “predicts”, “anticipate”, “to establish”, “believe”, “intend”, “ability to”, or statements that certain actions, events or results “may”, “could”, “would”, “might”, “will”, or are “likely” to be taken, occur or be achieved, or the negative of these words or other variations thereof, have been used to identify such forward-looking information. Specific forward-looking statements include, without limitation, all disclosure regarding future results of operations, economic conditions and anticipated courses of action.
The risks and uncertainties that may affect forward-looking statements include, among others, regulatory risk, United States border crossing and travel bans, reliance on licenses, expansion of facilities, competition, dependence on supply of cannabis and reliance on other key inputs, dependence on senior management and key personnel, general business risk and liability, regulation of the cannabis industry, change in laws, regulations and guidelines, compliance with laws, reliance on a single facility, limited operating history, vulnerability to rising energy costs, unfavourable publicity or consumer perception, product liability, risks related to intellectual property, product recalls, difficulties with forecasts, management of growth and litigation, many of which are beyond the control of The Valens Company. For a more comprehensive discussion of the risks faced by The Valens Company, and which may cause the actual financial results, performance or achievements of The Valens Company to be materially different from estimated future results, performance or achievements expressed or implied by forward-looking information or forward-looking statements, please refer to The Valens Company’s latest Annual Information Form filed with Canadian securities regulatory authorities at www.sedar.com or on The Valens Company’s website at www.thevalenscompany.com. The risks described in such Annual Information Form are hereby incorporated by reference herein. Although the forward-looking statements contained herein reflect management’s current beliefs and reasonable assumptions based upon information available to management as of the date hereof, The Valens Company cannot be certain that actual results will be consistent with such forward-looking information. The Valens Company cautions you not to place undue reliance upon any such forward-looking statements. The Valens Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law. Nothing herein should be construed as either an offer to sell or a solicitation to buy or sell securities of The Valens Company.
Cresco Labs Announces Opening of 10th Pennsylvania Dispensary in Ambler
January 18, 2022
CHICAGO--(BUSINESS WIRE)-- Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or “the Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, is expanding its Sunnyside brand in Pennsylvania with a new store located at 28 W Skippack Pike in Ambler. This location becomes the Company’s 10th store in Pennsylvania and 47th dispensary nationwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220118005232/en/
“We are thrilled to be opening our 10th store in Pennsylvania, a continuation of our strategy of going deeper in our footprint and tailoring to individual state dynamics,” said Charlie Bachtell, Cresco Labs’ CEO & Co-founder. “With our CPG and wholesale focus, we’ve been able to take the top market share in Pennsylvania according to Headset. Adding additional fully-owned retail will support our brand building and provide more access to Cresco Labs’ amazing products for patients across Pennsylvania.”
Located in the borough of Ambler north of Philadelphia, the dispensary is a few miles away from the Pennsylvania Turnpike, a superhighway transporting thousands of people daily east-west across the state. Sunnyside Ambler resides in an area home to large facilities operated by major pharmaceutical companies, including Johnson & Johnson, Merck and Janssen.
The dispensary will be open Monday through Thursday, 9 a.m. to 6 p.m., and Friday and Saturday, 9 a.m. to 7 p.m. Patients can place online orders, browsing live inventory, on www.Sunnyside.shop and pick up orders in-store the same day. Store phone is 267-405-2622.
For more information about Sunnyside, visit www.sunnyside.shop.
About Cresco Labs Inc.
Cresco Labs is one of the largest vertically integrated multistate cannabis operators in the United States, with a mission to normalize and professionalize the cannabis industry. Employing a consumer-packaged goods (“CPG”) approach, Cresco Labs is the largest wholesaler of branded cannabis products in the U.S. Its brands are designed to meet the needs of all consumer segments and comprised of some of the most recognized and trusted national brands including Cresco, High Supply, Mindy's Edibles, Good News, Remedi, Wonder Wellness Co. and FloraCal Farms. Sunnyside, Cresco Labs’ national dispensary brand, is a wellness-focused retailer created to build trust, education and convenience for both existing and new cannabis consumers. Recognizing that the cannabis industry is poised to become one of the leading job creators in the country, Cresco Labs operates the industry’s largest Social Equity and Educational Development initiative, SEED, which was established to ensure that all members of society have the skills, knowledge and opportunity to work and own businesses in the cannabis industry. Learn more about Cresco Labs at www.crescolabs.com.
Forward Looking Statements
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as, ‘may,’ ‘will,’ ‘should,’ ‘could,’ ‘would,’ ‘expects,’ ‘plans,’ ‘anticipates,’ ‘believes,’ ‘estimates,’ ‘projects,’ ‘predicts,’ ‘potential’ or ‘continue’ or the negative of those forms or other comparable terms. The Company’s forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to those risks discussed under “Risk Factors” in the Company’s Annual Information Form for the year ended December 31, 2020 filed on March 26, 2021, and other documents filed by the Company with Canadian securities regulatory authorities; and other factors, many of which are beyond the control of the Company. Readers are cautioned that the foregoing list of factors is not exhaustive. Because of these uncertainties, you should not place undue reliance on the Company’s forward-looking statements. No assurances are given as to the future trading price or trading volumes of Cresco Labs’ shares, nor as to the Company’s financial performance in future financial periods. The Company does not intend to update any of these factors or to publicly announce the result of any revisions to any of the Company’s forward-looking statements contained herein, whether as a result of new information, any future event or otherwise. Except as otherwise indicated, this press release speaks as of the date hereof. The distribution of this press release does not imply that there has been no change in the affairs of the Company after the date hereof or create any duty or commitment to update or supplement any information provided in this press release or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220118005232/en/
Media:
Jason Erkes, Cresco Labs
Chief Communications Officer
press@crescolabs.com
Investors:
investors@crescolabs.com
For general Cresco Labs inquiries:
312-929-0993
info@crescolabs.com
Source: Cresco Labs Inc.
Odyssey Group (ODYY) Stock Is A Long-Term Growth Machine?
By staff -January 13, 2022
Budweiser slipping golden cans into packs for a million-dollar prize
https://www.cbs17.com/news/check-this-out/budweiser-slipping-golden-cans-into-packs-for-a-million-dollar-prize/
by: Joe Millitzer, Nexstar Media Wire
Posted: Jan 13, 2022 / 08:52 AM EST / Updated: Jan 13, 2022 / 08:52 AM EST
There are actually two ways to enter Budweiser’s “Live Like a King” sweepstakes. (Anheuser-Busch InBev)
ST. LOUIS, M.O. (KTVI) – Anheuser-Busch is borrowing an idea from Willy Wonka with their new “Live Like a King” sweepstakes.
The company is placing 10,000 golden cans of beer (instead of tickets) in specially marked packs across the United States. Anyone who finds a golden can — or makes one — will be eligible to win the million-dollar grand prize if they post the image correctly.
Yes, there are actually two ways to enter this sweepstakes: Fans can randomly find a golden Budweiser can and snap a photo, or simply go to the brewer’s website and print a golden can. Those choosing the latter option can then wrap the image around an actual can and take a picture.
Unionization efforts spread across US for Amazon, Starbucks
Now comes the important part. Entrants must post a picture of the can to Facebook, Instagram or Twitter, tagging @budweiserusa and using the hashtags #LiveLikeAKing & #Sweepstakes.
Entries began being accepted Monday and the contest will last through Feb. 20.
Anheuser-Busch will hold a random drawing to choose the winner on “or about” February 21, 2022, according to the official rules. The winner will then be notified via direct message on social media, from that time they will have 48 hours to respond and accept the prize.
Odds of winning depend on the number of entries received.
MedMen’s Tracy McCourt Appointed President of West Hollywood Cannabis Organization
01/13/2022
https://investors.medmen.com/press-releases/press-release-details/2022/MedMens-Tracy-McCourt-Appointed-President-of-West-Hollywood-Cannabis-Organization/default.aspx
LOS ANGELES--(BUSINESS WIRE)-- MedMen Enterprises Inc. (“MedMen” or the “Company”) (CSE: MMEN) (OTCQB: MMNFF), a leading cannabis retailer with operations across the nation, today announced the appointment of Tracy McCourt, Chief Revenue Officer, to President of Emerald Village West Hollywood. Established in 2021, Emerald Village West Hollywood is the official marketing organization for licensed cannabis businesses in West Hollywood.
“It’s an honor to lead an organization dedicated to promoting West Hollywood’s vibrant cannabis industry,” said McCourt. “Working together with a group of diverse cannabis retailers in the community, we’re positioning WeHo as the capital of cannabis culture and curated experiences for tourists and locals alike.”
Emerald Village offers an extensive and eclectic range of cannabis attractions, including culinary, wellness, entertainment, nightlife, art and personalized experiences. Visitors can plan their cannabis adventures through the Emerald Village website – emeraldvillageweho.com – which features the latest on cannabis events, businesses and attractions in the area.
Current member organizations of Emerald Village West Hollywood include Alternative Herbal Health Services (AHHS), The Artist Tree, CALMA, LA Patients and Caregivers Group (LAPCG), MedMen, and Zen Healing Collective.
ABOUT MEDMEN:
MedMen is a premier American cannabis retailer with an operational footprint in California, Nevada, Illinois, Arizona, Massachusetts, and Florida. MedMen offers a robust selection of high-quality products, including MedMen-owned brands MedMen Red and LuxLyte through its premium retail stores, proprietary delivery service, as well as curbside and in-store pickup. MedMen Buds, an industry-first loyalty program, provides exclusive access to promotions, product drops and content. MedMen believes that a world where cannabis is legal and regulated is safer, healthier, and happier. Learn more about MedMen at www.medmen.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220113005205/en/
MedMen Media Contact:
Lisa Weser
MedMen@Trailblaze.co
MedMen Investor Relations Contact:
Investors@MedMen.com
Source: MedMen Enterprises Inc.
MedMen Expands Brand Portfolio With Boutique Strains From Fog City Farms
01/11/2022
https://investors.medmen.com/press-releases/press-release-details/2022/MedMen-Expands-Brand-Portfolio-With-Boutique-Strains-From-Fog-City-Farms/default.aspx
Sustainably-produced strains will join MedMen’s portfolio of coveted cannabis brands
LOS ANGELES--(BUSINESS WIRE)-- MedMen Enterprises Inc. (“MedMen” or the “Company”) (CSE: MMEN) (OTCQX: MMNFF), a leading cannabis retailer with operations across the nation, today announced it will carry new products from Fog City Farms, a Santa Cruz-based cannabis cultivation company specializing in sustainable growing and business practices, with an emphasis on boutique strains. Beginning January 23, unique small-batch strains cultivated in Fog City Farms’ state-of-the-art vertical growing platform will be available at select MedMen locations across California.
“MedMen is proud to stock the latest strains from Fog City Farms, a sustainably-minded cultivator with a deeply-rooted history in Northern California’s legendary cannabis scene,” said Tyson Rossi, SVP Product and Revenue, MedMen. “Cultivated with forward-thinking farming practices and a focus on boutique cultivars, Fog City Farms’ cannabis products mark another strategic addition to our diverse brand roster, which we continue to expand in pursuit of best-in-class products for our growing customer base.”
MedMen will stock a wide range of Fog City Farms products, including the brand’s inaugural limited-edition collaboration with Hashbone – a line of premium, solventless hash-infused pre-rolls featuring artisan blends of top-shelf flower and cold-water bubble hash. This latest portfolio expansion is a testament to MedMen’s new era of post-turnaround accelerated growth and demonstrates the Company’s commitment to trusted, high-quality products and unparalleled service. MedMen’s full inventory of vaporizers, concentrates, pre-rolls and flower are available in stores or through the Company’s proprietary online ordering service for all patients and Buds rewards members.
To purchase MedMen products, please visit www.medmen.com, or find a dispensary near you at https://www.medmen.com/stores.
ABOUT MEDMEN:
MedMen is a premier American cannabis retailer with an operational footprint in California, Nevada, Illinois, Arizona, Massachusetts, and Florida. MedMen offers a robust selection of high-quality products, including MedMen-owned brands MedMen Red and LuxLyte through its premium retail stores, proprietary delivery service, as well as curbside and in-store pickup. MedMen Buds, an industry-first loyalty program, provides exclusive access to promotions, product drops and content. MedMen believes that a world where cannabis is legal and regulated is safer, healthier, and happier. Learn more about MedMen at www.medmen.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220111005417/en/
MedMen Media Contact:
Lisa Weser
MedMen@Trailblaze.co
MedMen Investor Relations Contact:
Investors@MedMen.com
Source: MedMen Enterprises Inc.
MedMen Announces Termination of Investment Agreement
01/03/2022
https://investors.medmen.com/press-releases/press-release-details/2022/MedMen-Announces-Termination-of-Investment-Agreement/default.aspx
LOS ANGELES--(BUSINESS WIRE)-- MedMen Enterprises Inc. (“MedMen” or the “Company”) (CSE: MMEN) (OTCQX: MMNFF), a premier cannabis retailer with operations across the United States, today announced its termination of that certain Investment Agreement, dated as of February 25, 2021 (the “Investment Agreement”), by and among MedMen NY, Inc., a New York corporation, MM Enterprises USA, LLC, a Delaware limited liability company, AWH New York, LLC, a Delaware limited liability company, and Ascend Wellness Holdings, Inc. (“AWH”), a Delaware corporation. The Investment Agreement, pursuant to which AWH would have invested into MedMen’s New York Operations, was previously announced in a press release dated as of February 25, 2021.
ABOUT MEDMEN:
MedMen is a premier American cannabis retailer with an operational footprint in California, Nevada, Illinois, Arizona, Massachusetts, and Florida. MedMen offers a robust selection of high-quality products, including MedMen-owned brands MedMen Red and LuxLyte through its premium retail stores, proprietary delivery service, as well as curbside and in-store pickup. MedMen Buds, an industry-first loyalty program, provides exclusive access to promotions, product drops and content. MedMen believes that a world where cannabis is legal and regulated is safer, healthier, and happier. Learn more about MedMen at www.medmen.com.
Cautionary Note Regarding Forward-Looking Information and Statements:
This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only MedMen’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of MedMen’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “would have”. This forward-looking information is based on certain assumptions made by management and other factors used by management in developing such information. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and MedMen does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. Forward-looking statements contained in this news release are expressly qualified by this cautionary note.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220103005249/en/
MedMen Media Contact:
Lisa Weser
MedMen@Trailblaze.co
MedMen Investor Relations Contact:
Investors@MedMen.com
Source: MedMen Enterprises Inc.
FIRE & FLOWER ANNOUNCES PARTICIPATION IN UPCOMING JANUARY CONFERENCES
JANUARY, 12, 2022
https://investors.fireandflower.com/news/news-details/2022/FIRE--FLOWER-ANNOUNCES-PARTICIPATION-IN-UPCOMING-JANUARY-CONFERENCES/default.aspx
TORONTO, Jan. 12, 2022 /CNW/ - Fire & Flower Holdings Corp. ("Fire & Flower" or the "Company") (TSX: FAF) (OTCQX: FFLWF), a leading, technology-powered, cannabis retailer, today announced that the Fire & Flower will participate at the following upcoming conferences this month at which Trevor Fencott, CEO of Fire & Flower, will present.
ATB Capital Markets 10th Annual Institutional Investor Conference is being held Thursday, January 13, 2022. Mr. Fencott will be participating on the panel "Retail and the Art of Data" at 2:00 pm Eastern. To register for this event please click here. (The link in the PR does not work.)
KCSA Cannabis Virtual Investor Conference at 12:30pm Eastern on Thursday, January 20, 2022. To register for this event please click here.
https://www.virtualinvestorconferences.com/events/event-details/kcsa-cannabis-virtual-investor-conference-0
About Fire & Flower
Fire & Flower is a leading, technology-powered, adult-use cannabis retailer with more than 100 corporate-owned stores in its network. The Company leverages its wholly-owned technology development subsidiary, Hifyre Inc., to continually advance its proprietary retail operations model while also providing additional independent high-margin revenue streams. Fire & Flower guides consumers through the complex world of cannabis through education-focused, best-in-class retailing while the HifyreTM digital retail and analytics platform empowers retailers to optimize their connections with consumers. The Company's leadership team combines extensive experience in the technology, cannabis and retail industries.
Through the strategic investment of Alimentation Couche-Tard (owner of Circle K convenience stores), the Company has set its sights on global expansion as new cannabis markets emerge and is poised to expand into the United States when permitted through its strategic licensing agreement with Fire & Flower U.S. Holdings upon the occurrence of certain changes to the cannabis regulatory regime.
Fire & Flower is a multi-banner cannabis retail operator that owns and operates the Fire & Flower, Friendly Stranger, Happy Dayz and Hotbox brands. Fire & Flower Holdings Corp. owns all issued and outstanding shares in Fire & Flower Inc. and Friendly Stranger Holdings Corp., licensed cannabis retailers that own and operate cannabis retail stores in the provinces of Alberta, Saskatchewan, Manitoba, British Columbia and Ontario, and the Yukon territory.
To learn more about Fire & Flower, visit www.fireandflower.com.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
This news release contains certain forward-looking information within the meaning of applicable Canadian securities laws ("forward-looking statements"). All statements other than statements of present or historical fact are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "anticipate", "achieve", "could", "believe", "plan", "intend", "objective", "continuous", "ongoing", "estimate", "outlook", "expect", "project" and similar words, including negatives thereof, suggesting future outcomes or that certain events or conditions "may" or "will" occur. These statements are only predictions.
Forward-looking statements are based on the opinions and estimates of management of Fire & Flower at the date the statements are made based on information then available to the Fire & Flower. Various factors and assumptions are applied in drawing conclusions or making the forecasts or projections set out in forward-looking statements, including market conditions and the business of the Company. Forward-looking statements are subject to and involve a number of known and unknown, variables, risks and uncertainties, many of which are beyond the control of Fire & Flower, which may cause Fire & Flower's actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. Such factors, among other things, include: regulatory and other approvals or consents; fluctuations in general macroeconomic conditions; fluctuations in securities markets; the impact of the COVID-19 pandemic; the ability of the Company to successfully achieve its business objectives and political and social uncertainties.
No assurance can be given that the expectations reflected in forward-looking statements will prove to be correct. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. Additional information regarding risks and uncertainties relating to the Company's business are contained under the heading "Risk Factors" in the Company's annual information form dated April 30, 2021 and the heading "Risks and Uncertainties" in the management discussion and analysis for the quarter ended October 30, 2021 filed on its issuer profile on SEDAR at www.sedar.com . The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.
No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
SOURCE Fire & Flower Holdings Corp.
"Live Diamonds" is a trade name generated by an extraction method Valens has had for years. Can anyone tell me what the product actually is? What makes it different and better?
Trulieve First in Florida Market to Offer Live Diamonds, Company's Latest Hydrocarbon Extraction Product
January 10, 2022 at 9:00 AM EST
https://investors.trulieve.com/news-releases/news-release-details/trulieve-first-florida-market-offer-live-diamonds-companys
All units of Live Diamonds by Muse sold out within 24 hours
TALLAHASSEE, Fla., Jan. 10, 2022 /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced the launch of Live Diamonds by Muse™. Live Diamonds are the latest innovation from Trulieve's state-of-the-art hydrocarbon extraction lab, the only one of its kind in the state of Florida. The initial product release of 500 units sold out within 24 hours, and Trulieve anticipates another batch of Live Diamonds to become available for sale in February 2022. The launch strain, White Fire Alien, exhibits subtle, natural flavors with a retail price of $45 for 0.5 grams.
"Trulieve is excited to be Florida's first and only dispensary to offer patients the benefits of high-quality cannabis concentrates produced through hydrocarbon extraction, especially Live Diamonds by Muse," said Kim Rivers, CEO of Trulieve. "Due to the delicate and complex production process, this product will only be available in limited quantities, however we look forward to expanding patient access and continuing to deliver innovative products to our valued patient base here in Florida."
Live Diamonds are created using a proprietary blend of propane and butane in Trulieve's hydrocarbon extraction lab via TruFlower that has been frozen immediately at the time of harvest. The result of the "diamond mining" and production process locks in volatile terpenes and produces a strain-specific, full-spectrum cannabis concentrate that exhibits subtle, natural flavors. "Live" products are generally described as a truly enhanced experience in terms of flavor and appear to offer a broader set of effects for users.
Trulieve patients across Florida can choose from the largest selection of THC and CBD products available in a variety of consumption methods, including smokable flower, concentrates, edibles, capsules, syringes, tinctures, topical creams, vaporizers, and more. Patients have access to beloved brands such as Bellamy Brothers, Bhang, Binske, Blue River, Black Tuna, Love's Oven, O.pen, and Sunshine Cannabis, all available exclusively at Trulieve in Florida.
For more information, to find a location, or to learn how to become a registered patient, please visit Trulieve.com and connect on Instagram or Facebook. Learn more about Muse at @meet.your.muse.
About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S. operating in 11 states, with leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com.
Facebook: @Trulieve
Instagram: @Trulieve
Twitter: @Trulieve
Investor Contact
Christine Hersey, Director of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com
Media Contact
Rob Kremer, Executive Director of Corporate Communications
+1 (404) 218-3077
Robert.Kremer@Trulieve.com
Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/trulieve-first-in-florida-market-to-offer-live-diamonds-companys-latest-hydrocarbon-extraction-product-301457166.html
SOURCE Trulieve Cannabis Corp.
Kinder Morgan Announces Fourth Quarter ‘21 Earnings Webcast
01/12/2022
https://ir.kindermorgan.com/news/news-details/2022/Kinder-Morgan-Announces-Fourth-Quarter-21-Earnings-Webcast/default.aspx
HOUSTON--(BUSINESS WIRE)-- Kinder Morgan, Inc. (NYSE: KMI) today announced it will release fourth quarter 2021 earnings results on Wednesday, January 19, 2022 after market close and will hold a live webcast and conference call.
What: Kinder Morgan Fourth Quarter ‘21 Earnings Results Webcast
When: January 19, 2022, at 3:30 p.m. CT, 4:30 p.m. ET
Where: http://ir.kindermorgan.com/presentations-webcasts
How: Live over the Internet by logging on to the web at the above address, or by phone (listen-only) by dialing 1-210-234-0073 and entering the passcode 1182662.
If you are unable to listen during the live webcast, the call will be archived at www.kindermorgan.com. A recording of the conference call will also be available for replay one hour after the call until the end of the day on February 19, 2022. To access the replay, please dial 1-203-369-1438 and enter passcode 24661.
About Kinder Morgan, Inc.
Kinder Morgan, Inc. (NYSE: KMI) is one of the largest energy infrastructure companies in North America. Access to reliable, affordable energy is a critical component for improving lives around the world. We are committed to providing energy transportation and storage services in a safe, efficient, and environmentally responsible manner for the benefit of people, communities and businesses we serve. We own an interest in or operate approximately 83,000 miles of pipelines and 144 terminals. Our pipelines transport natural gas, renewable fuels, refined petroleum products, crude oil, condensate, CO2 and other products, and our terminals store and handle various commodities including gasoline, diesel fuel, chemicals, ethanol, metals and petroleum coke. Learn more about our renewables initiatives on the low carbon solutions page at www.kindermorgan.com.
Media Relations
Dave Conover
newsroom@kindermorgan.com
Investor Relations
(713) 369-9490
km_ir@kindermorgan.com
www.kindermorgan.com
Source: Kinder Morgan, Inc.
Trulieve Investors Presentation January 2022
https://investors.trulieve.com/static-files/6e64df77-d879-4453-83fb-e6e1ca0edbe5
Investor Presentation - January 2022
https://s23.q4cdn.com/166212319/files/doc_presentations/2022/GreenThumb-Investor-Presentation_January2022.pdf
I love the video. Thanks.
Irwin Simon is duplicating his Hain Celestial Group, Inc. mega-success.
https://freemanmag.tulane.edu/2020/02/28/irwin-simons-second-act/
If legalization happens in the USA and EU, Simon will bolt-on-synergistic acquisitions, pushing revenues towards his stated goal of $4B by 2026.
It's in his DNA.
Legalization also means THC is going into all of Tilray's beverages, and MedMen becomes a wholly owned subsidiary.
CC Pharma is the leading cannabis pharmaceutical company in the EU. The foothold is firmly established.
It's pretty obvious where America stands on legalization. It's a few republicans defying their constituents wishes that is keeping rec legal weed from being the law of the land.
The dems opposing them in 2022 need to make it a social and economic issue in their campaigns. Tie the two together.
Forget about social equity.
Number one is freedom of choice to consume cannabis. Number two is tax revenues. Force the republicans to either come around or state their beliefs to be contrary to their constituents.
Sweetwater is the 11th largest craft brewer in the USA. Tilray bought a money making profitable brewery. Sweetwater is a ready-made avenue to the USA cannabis beverage market on day one of legalization, without having to pay a cannabis multiple. Super smart move; make money while patiently waiting for USA legalization.
Fantastic news! Thanks for the update. Clears the way for Tilray's full beverage control with Sweetwater, Breckenridge and others they are bolting on.
I couldn't be happier, especially since BUD never, ever performed. BUD was a DUD.
Clears away the BS and simplifies the path to dominate beverages without a profit split.
I missed the news. Thanks for posting.
Hopefully the rules in Germany are less onerous than they are in the USA and Canada. Maybe they might actually enable the new industry.
Maybe even some stimulus like access to banking.
Agree with every sentence.
Expect more bolt on acquisitions. Expect cannabis to be an election topic in races. Republicans need to be put on the spot.
Price $7.51...Day's Change +$1.09 (+16.98%) Volume(Heavy Day) Today's volume of 20,086,943 shares is on pace to be much greater than TLRY's 10-day average volume of 23,800,052 shares.
January 10, 2022 9:40am ET
The plan is shooting for $4B and making money.
Money in w/o dilution. --->>> Odyssey Group International Receives Donation to Support a Treatment for Concussion and forms Community Partnership with the Erase PTSD Now Foundation
https://finance.yahoo.com/news/odyssey-group-international-receives-donation-133000843.html
Odyssey Group Intl Inc.
Mon, January 10, 2022, 8:30 AM·4 min read
In this article:
ODYY
-7.14%
Explore the topics mentioned in this article
IRVINE, CA, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTC Pink: ODYY) (the "Company" or "Odyssey"), a company focused on developing unique, life-saving medical products, today announced that it has received a donation in the amount of $500,000 in partnership with the Erase PTSD Now organization and the Glenn Greenberg and Linda Vester Foundation. These funds will be used to progress the Phase 1 human clinical trials for drug candidate PRV-002 for the treatment of concussion.
“We are honored to have formed a partnership with Erase PTSD Now and to have been chosen by Glenn and Linda’s Foundation for such a tremendous gift to advance our drug trials. We are currently in a Phase I safety study and these funds will allow us to make significant progress and prepare for the Phase II trials,” commented Michael Redmond, CEO of Odyssey Group International.
“We have a highly respected record of helping Post-Traumatic Stress Disorder (PTSD) patients. We are excited to work with Odyssey and our PTSD sufferers to better understand the link between concussion and PTSD. Like Odyssey’s scientific team, we believe that if our veterans are treated early on with a brain-targeted agent they will have better psychological outcomes,” commented, Dr. Eugene Lipov, Chief Scientific Officer of Erase PTSD Now Foundation.
Glen and Linda have a passion for helping military veterans. They recognize the unique medical conditions they face and how vital it is that they receive specialty care. Unfortunately, many veterans develop PTSD. PTSD symptoms can include unwanted memories, depression, anxiety, avoidance behaviors and panic disorder. Worst of all, PTSD is associated with a higher incidence of suicide. Glenn and Linda’s Foundation works directly with the Erase PTSD Now Foundation. Erase PTSD Now provides funding for the sympathetic modulation procedure. This procedure has a very high efficacy rate in reducing PTSD symptoms and mental health dysfunction, as well as improving quality of life.
Concussions have been linked to the increased incidence of PTSD. Odyssey is developing the first pharmaceutical to treat concussion in the acute phase of injury. A field deliverable intranasal device filled with their drug, PRV-002 can be kept in the medic’s bag or the soldier’s pocket for “buddy” aid immediately following a concussion. Reducing inflammation of the brain early on can significantly improve outcomes and return our soldiers back to action faster and more safely.
Odyssey Group International and Erase PTSD Now have formed a community-based partnership to collect data on PTSD patients who have also sustained a concussion. Measures for patient symptom severity, short-term memory and thought processing speed will be the cornerstone for better understanding the link between these two conditions. This partnership will benefit PTSD patients by helping them understand how brain trauma can lead to psychological sequelae and assist Odyssey in the design of future military arms of their clinical trials.
For more information about the Erase PTSD NOW organization, visit their website at https://eraseptsdnow.org/.
About Odyssey Group International, Inc.
Odyssey Group International, Inc. (OTC Pink: ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners. Odyssey is changing its name to Odyssey Health, Inc. to reflect our corporate mission and focus.
We encourage our shareholders to visit: http://www.odysseygi.com or Twitter: @OdysseyGroupIn1.
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete the Phase 1 trial, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Contact:
Odyssey Group International
Preya Narain
info@odysseygi.com
Nice to see the synergies actually coming into play on Simon's timeline. The foresight adds confidence going forward.
No need for excuses. The man has a plan and he is executing. I like that.
Correction LCK--->>>The Philly store is two blocks from city hall and next to the Reading Terminal Market. THAT'S CENTER CITY; the "heart of Philadelphia, inside the "yellow-bullseye".
Cresco Labs Announces Conference Participation for January 2022
January 06, 2022
https://investors.crescolabs.com/investors/press-releases/press-release-details/2022/Cresco-Labs-Announces-Conference-Participation-for-January-2022/default.aspx
CHICAGO--(BUSINESS WIRE)-- Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or “the Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, today announced its executive team will participate in the following conferences in January 2022:
ATB 10th Annual Institutional Investor Conference, January 13, 2022:
Chief Commercial Officer, Greg Butler will participate in a panel discussion and management will participate in one-on-one meetings.
Details on the panel are shown below:
Title: Brand Building and Leadership: The Good, The Bad, The Ugly
Date: Thursday, January 13, 2022
Time: 9:00 a.m. ET
Webcast Link: https://bit.ly/3pY9tLv
24th Annual Needham Virtual Growth Conference, January 14, 2022:
Management will participate in one-on-one meetings.
About Cresco Labs Inc.
Cresco Labs is one of the largest vertically integrated multistate cannabis operators in the United States, with a mission to normalize and professionalize the cannabis industry. Employing a consumer-packaged goods (“CPG”) approach, Cresco Labs is the largest wholesaler of branded cannabis products in the U.S. Its brands are designed to meet the needs of all consumer segments and comprised of some of the most recognized and trusted national brands including Cresco, High Supply, Mindy's Edibles, Good News, Remedi, Wonder Wellness Co. and FloraCal Farms. Sunnyside, Cresco Labs’ national dispensary brand, is a wellness-focused retailer created to build trust, education and convenience for both existing and new cannabis consumers. Recognizing that the cannabis industry is poised to become one of the leading job creators in the country, Cresco Labs operates the industry’s largest Social Equity and Educational Development initiative, SEED, which was established to ensure that all members of society have the skills, knowledge and opportunity to work and own businesses in the cannabis industry. Learn more about Cresco Labs at www.crescolabs.com.
Facebook: Cresco Labs
Instagram: Cresco Labs
Twitter: Cresco Labs
View source version on businesswire.com: https://www.businesswire.com/news/home/20220106005179/en/
Media:
Jason Erkes, Cresco Labs
Chief Communications Officer
press@crescolabs.com
Investors:
investors@crescolabs.com
For general Cresco Labs inquiries:
312-929-0993
info@crescolabs.com
Source: Cresco Labs
Trulieve Announces Grand Opening of its Affiliate's (Chamounix Ventures, LLC) Philadelphia Dispensary
January 7, 2022 at 9:10 AM EST
https://investors.trulieve.com/news-releases/news-release-details/trulieve-announces-grand-opening-its-affiliates-chamounix
Medical marijuana dispensary opens Saturday, January 8
TALLAHASSEE, Fla., Jan. 7, 2022 /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States, today announced the opening of a new Trulieve-branded medical marijuana dispensary through its affiliate, Chamounix Ventures, LLC. The dispensary at 1222 Arch St. is in the Center City section of Philadelphia. This location becomes the Company's 160th owned, operated or affiliated dispensary nationwide.
Trulieve 1222 Arch St. Philadelphia
Located in the heart of Philadelphia, between City Hall and Reading Terminal Market, the dispensary will be open Monday – Saturday from 9am – 8pm and on Sunday from 10am – 6pm. Patients can choose from Trulieve's selection of premium whole flower products, including TruFlower and Cultivar Collection, as well as a wide range of vapes, tinctures, topicals and ingestibles.
"We are proud to begin the New Year by demonstrating our ongoing commitment to serving Pennsylvania's patient community through high quality and reliable medical marijuana products," said Kim Rivers, CEO of Trulieve. "We look forward to welcoming patients and strengthening community connections in this cornerstone market."
Additional Trulieve-affiliated dispensaries in Pennsylvania are located in Camp Hill, Cranberry Township, Devon, Harrisburg, Johnstown, King of Prussia, Pittsburgh, Reading, Scranton, Washington, Whitehall, York and Zelienople.
To find a location or to learn how to become a registered patient, visit Trulieve.com, follow us on Instagram at trulieve_pa or connect with Trulieve PA on Facebook.
About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S. operating in 11 states, with leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com.
Facebook: @Trulieve
Instagram: @Trulieve_
Twitter: @Trulieve
Investor Contact
Christine Hersey, Director of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com
Media Contact
Rob Kremer, Executive Director of Corporate Communications
+1 (404) 218-3077
Robert.Kremer@Trulieve.com
MATTIO Communications
Trulieve@Mattio.com
Trulieve logo (PRNewsfoto/Trulieve Cannabis Corp.)
Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/trulieve-announces-grand-opening-of-its-affiliates-chamounix-ventures-llc-philadelphia-dispensary-301456254.html
SOURCE Trulieve Cannabis Corp.
THE VALENS COMPANY TO PARTICIPATE IN ATB CAPITAL MARKETS’ 10TH ANNUAL INSTITUTIONAL INVESTOR CONFERENCE
https://thevalenscompany.com/press-releases/the-valens-company-to-participate-in-atb-capital-markets-10th-annual-institutional-investor-conference/
KELOWNA, BC, Jan. 7, 2022 /CNW/ – The Valens Company Inc. (TSX: VLNS) (Nasdaq: VLNS) (the “Company” “The Valens Company” or “Valens”), a leading manufacturer of cannabis products, is pleased to announce that Tyler Robson, Chief Executive Officer and Chair of The Valens Company, will participate in the ATB Capital Markets 10th Annual Institutional Investor Conference being held January 13, 2022. Management will also be participating in a day of buyside meetings.
Mr. Robson is scheduled to join Frederico Gomes, Vice President Institutional Research, for a fireside chat titled “Model Evolution Supports Margin Expansion” on Thursday January 13, 2022, at 1:20 PM ET. Investors can sign up for the virtual conference here.
At Valens, it’s Personal.
About The Valens Company
The Valens Company is a leading manufacturer of cannabis products with a mission to bring the benefits of cannabis to the world. The Company provides proprietary cannabis processing services, in addition to best-in-class product development, manufacturing, and commercialization of cannabis consumer packaged goods. The Valens Company’s high-quality products are formulated for the medical, health and wellness, and recreational consumer segments, and are offered across all cannabis product categories with a focus on quality and innovation. The Company also manufactures, distributes, and sells a wide range of CBD products in the United States through its subsidiary Green Roads, and distributes medicinal cannabis products to Australia through its subsidiary Valens Australia. In partnership with brand houses, consumer packaged goods companies and licensed cannabis producers around the globe, the Company continues to grow its diverse product portfolio in alignment with evolving cannabis consumer preferences in key markets. Through Valens Labs, the Company is setting the standard in cannabis testing and research and development with Canada’s only ISO17025 accredited analytical services lab, named The Centre of Excellence in Plant-Based Science by partner and scientific world leader Thermo Fisher Scientific. Discover more on The Valens Company at http://www.thevalenscompany.com.
Notice regarding Forward Looking Statements
All information included in this press release, including any information as to the future financial or operating performance and other statements of The Valens Company that express management’s expectations or estimates of future performance, other than statements of historical fact, constitute forward-looking information or forward-looking statements within the meaning of applicable securities laws and are based on expectations, estimates and projections as of the date hereof. Forward-looking statements are included for the purpose of providing information about management’s current expectations and plans relating to the future. Wherever possible, words such as “plans”, “expects”, “scheduled”, “trends”, “forecasts”, “future”, “indications”, “potential”, “estimates”, “predicts”, “anticipate”, “to establish”, “believe”, “intend”, “ability to”, or statements that certain actions, events or results “may”, “should”, “could”, “would”, “might”, “will”, or are “likely” to be taken, occur or be achieved, or the negative of these words or other variations thereof, have been used to identify such forward-looking information. Specific forward-looking statements include, without limitation, all disclosure regarding future results of operations, future outcomes of transactions, economic conditions, and anticipated courses of action. Investors and other parties are advised that there is not necessarily any correlation between the number of SKUs manufactured and shipped and revenue and profit, and undue reliance should not be placed on such information.
The risks and uncertainties that may affect forward-looking statements include, among others, Canadian regulatory risk, Australian regulatory risk, U.S. regulatory risk, U.S. border crossing and travel bans, the uncertainties, effects of and responses to the COVID-19 pandemic, reliance on licenses, expansion of facilities, competition, dependence on supply of cannabis and reliance on other key inputs, dependence on senior management and key personnel, general business risk and liability, regulation of the cannabis industry, change in laws, regulations and guidelines, compliance with laws, limited operating history, vulnerability to rising energy costs, unfavourable publicity or consumer perception, product liability, risks related to intellectual property, product recalls, difficulties with forecasts, management of growth and litigation, many of which are beyond the control of The Valens Company. For a more comprehensive discussion of the risks faced by The Valens Company, and which may cause the actual financial results, performance or achievements of The Valens Company to be materially different from estimated future results, performance or achievements expressed or implied by forward-looking information or forward-looking statements, please refer to The Valens Company’s latest Annual Information Form filed with Canadian securities regulatory authorities at www.sedar.com or on The Valens Company’s website at www.thevalenscompany.com. The risks described in such Annual Information Form are hereby incorporated by reference herein. Although the forward-looking statements contained herein reflect management’s current beliefs and reasonable assumptions based upon information available to management as of the date hereof, The Valens Company cannot be certain that actual results will be consistent with such forward-looking information. The Valens Company cautions you not to place undue reliance upon any such forward-looking statements. The Valens Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law. Nothing herein should be construed as either an offer to sell or a solicitation to buy or sell securities of The Valens Company.
SOURCE The Valens Company Inc.
For further information: Jeff Fallows, The Valens Company, Investor Relations, ir@thevalenscompany.com, 1.647.956.8254; KCSA Strategic Communications, Phil Carlson, VLNS@kcsa.com, 1.212.896.1233; Media: KCSA Strategic Communications, Anne Donohoe, adonohoe@kcsa.com, 1 212.896.1265
RELATED LINKS
https://thevalenscompany.com/
ABOUT THE VALENS COMPANY
The Valens Company is a global leader in the end-to-end development and manufacturing of innovative, cannabinoid-based products. The Valens Company is focused on being the partner of choice for leading Canadian and international cannabis brands by providing best-in-class, proprietary services including CO2, ethanol, hydrocarbon, solvent-less and terpene extraction, analytical testing, formulation and product development and custom manufacturing. Valens is the largest third-party extraction company in Canada with an annual capacity of 425,000 kg of dried cannabis and hemp biomass at our purpose-built facility in Kelowna, British Columbia which is in the process of becoming European Union (EU) Good Manufacturing Practices (GMP) compliant. The Valens Company currently offers a wide range of product formats, including tinctures, two-piece caps, soft gels, oral sprays and vape pens as well as beverages, concentrates, topicals, edibles, injectables, natural health products and has a strong pipeline of next-generation products in development for future release. Finally, The Valens Company’s wholly-owned subsidiary Valens Labs is a Health Canada licensed ISO 17025 accredited cannabis testing lab providing sector-leading analytical services and has partnered with Thermo Fisher Scientific to develop a Centre of Excellence in Plant-Based Science. For more information, please visit https://thevalenscompany.com. The Valens Company’s investor deck can be found specifically at https://thevalenscompany.com/investors/.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Jeff Fallows
The Valens Company
Investor Relations
ir@thevalenscompany.com
1 647.956.8254
KCSA Strategic Communications
Phil Carlson / Elizabeth Barker
VLNS@kcsa.com
1 212.896.1233 / 1 212.896.1203
Media
KCSA Strategic Communications
Anne Donohoe
adonohoe@kcsa.com
1 212.896.1265
NOTICE REGARDING FORWARD LOOKING STATEMENTS
All information included in this press release, including any information as to the future financial or operating performance and other statements of The Valens Company that express management’s expectations or estimates of future performance, other than statements of historical fact, constitute forward-looking information or forward-looking statements within the meaning of applicable securities laws and are based on expectations, estimates and projections as of the date hereof. Forward-looking statements are included for the purpose of providing information about management’s current expectations and plans relating to the future. Wherever possible, words such as “plans”, “expects”, “scheduled”, “trends”, “indications”, “potential”, “estimates”, “predicts”, “anticipate”, “to establish”, “believe”, “intend”, “ability to”, or statements that certain actions, events or results “may”, “could”, “would”, “might”, “will”, or are “likely” to be taken, occur or be achieved, or the negative of these words or other variations thereof, have been used to identify such forward-looking information. Specific forward-looking statements include, without limitation, all disclosure regarding future results of operations, economic conditions and anticipated courses of action.
The risks and uncertainties that may affect forward-looking statements include, among others, regulatory risk, United States border crossing and travel bans, reliance on licenses, expansion of facilities, competition, dependence on supply of cannabis and reliance on other key inputs, dependence on senior management and key personnel, general business risk and liability, regulation of the cannabis industry, change in laws, regulations and guidelines, compliance with laws, reliance on a single facility, limited operating history, vulnerability to rising energy costs, unfavourable publicity or consumer perception, product liability, risks related to intellectual property, product recalls, difficulties with forecasts, management of growth and litigation, many of which are beyond the control of The Valens Company. For a more comprehensive discussion of the risks faced by The Valens Company, and which may cause the actual financial results, performance or achievements of The Valens Company to be materially different from estimated future results, performance or achievements expressed or implied by forward-looking information or forward-looking statements, please refer to The Valens Company’s latest Annual Information Form filed with Canadian securities regulatory authorities at www.sedar.com or on The Valens Company’s website at www.thevalenscompany.com. The risks described in such Annual Information Form are hereby incorporated by reference herein. Although the forward-looking statements contained herein reflect management’s current beliefs and reasonable assumptions based upon information available to management as of the date hereof, The Valens Company cannot be certain that actual results will be consistent with such forward-looking information. The Valens Company cautions you not to place undue reliance upon any such forward-looking statements. The Valens Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law. Nothing herein should be construed as either an offer to sell or a solicitation to buy or sell securities of The Valens Company.
CVS Health to hold fourth quarter and full year 2021 earnings conference call
Thursday, January 6, 2022
WOONSOCKET, R.I. — CVS Health® (NYSE: CVS) will hold a conference call with analysts and investors on Wednesday, February 9, 2022, at 8:00 a.m. ET to discuss fourth quarter and full year 2021 financial results.
An audio webcast of the conference call will be broadcast simultaneously through the Investor Relations portion of the CVS Health website for all interested parties. To access the webcast, visit http://investors.cvshealth.com. The webcast will be archived and available on the website for one year following the conference call.
About CVS Health
CVS Health is the leading health solutions company, delivering care like no one else can. We reach more people and improve the health of communities across America through our local presence, digital channels and approximately 300,000 dedicated colleagues including more than 40,000 physicians, pharmacists, nurses, and nurse practitioners. Wherever and whenever people need us, we help them with their health whether that's managing chronic diseases, staying compliant with their medications, or accessing affordable health and wellness services in the most convenient ways. We help people navigate the health care system and their personal health care by improving access, lowering costs and being a trusted partner for every meaningful moment of health. And we do it all with heart, each and every day. Learn more at www.cvshealth.com.
Love this: MediPharm Labs has no other material debt and full ownership of its assets, which includes two GMP facilities – one in the province of Ontario, Canada and the other in the state of Victoria, Australia. Other major assets include manufacturing infrastructure and equipment.
MediPharm Labs Completes Payment of All Convertible Debt
January 05, 2022 07:00 ET | Source: MediPharm Labs Corp.
https://www.globenewswire.com/news-release/2022/01/05/2361498/0/en/MediPharm-Labs-Completes-Payment-of-All-Convertible-Debt.html
...
TORONTO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce that it has completed all payments required under its 2020 $41 million unsecured convertible debt.
“MediPharm continues on its plan and path to profitability, and paying off our convertible debt in full is a major milestone on that path,” said Bryan Howcroft, CEO, MediPharm Labs. “Being essentially debt free with a strong cash position adds even more longevity to our business. As part of our growing nascent industry, this advantageous position differentiates us from some of our peers who may not have the runway to realize the industry’s full potential.”
On June 8, 2020, the Company closed a private placement with an US institutional investor for gross proceeds of $37.8 million through the issuance of two senior unsecured convertible notes. Starting in October 2020, the notes amortized through bi-monthly installment payments payable, in cash or shares, on the first and tenth business day of each month prior to the maturity date of June 8, 2023. During the interim period between payment dates, the holder of the notes had the option to convert accelerated installment amounts, in whole or in part at an installment conversion price calculated in accordance with the terms of the notes. As of December 31, 2021, the entire debt has been repaid in full through both cash installments and share accelerations. This extinguishes the debt in full 18 months before the maturity date.
MediPharm Labs has no other material debt and full ownership of its assets, which includes two GMP facilities – one in the province of Ontario, Canada and the other in the state of Victoria, Australia. Other major assets include manufacturing infrastructure and equipment.
The Company is now debt agreement free with a clean balance sheet and strong cash position. This position paired with a robust plan to reduce overhead, operating expenses and general and administrative expenses gives MediPharm Labs longevity to execute on its sales contracts and pipeline.
Makes no money. Completely changed over top management last year.
Trulieve Announces January 2022 Investor Conference Participation
January 5, 2022 at 8:00 AM EST
https://investors.trulieve.com/news-releases/news-release-details/trulieve-announces-january-2022-investor-conference
TALLAHASSEE, Fla., Jan. 5, 2022 /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States, today announced upcoming participation in various investor conferences in January.
ICR Conference, January 10, 2022: Founder and CEO Kim Rivers will participate in a fireside chat and investor meetings.
ATB Capital Markets 10th Annual Institutional Investor Conference, January 13, 2022: President Steve White will participate in a panel discussion and investor meetings.
Needham 24th Annual Growth Conference, January 14, 2022: Founder and CEO Kim Rivers will participate in a panel discussion and investor meetings.
About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S. operating in 11 states, with leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com.
Facebook: @Trulieve
Instagram: @Trulieve
Twitter: @Trulieve
Investor Contact
Christine Hersey, Director of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com
Media Contact
Rob Kremer, Executive Director of Corporate Communications
+1 (404) 218-3077
Robert.Kremer@Trulieve.com
Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/trulieve-announces-january-2022-investor-conference-participation-301454501.html
SOURCE Trulieve Cannabis Corp.
El Blunto Partners with Trulieve to Launch Exclusively in Arizona at Harvest Dispensaries
This marks the first expansion into another state for one of California's top cannabis brands.
https://www.prnewswire.com/news-releases/el-blunto-partners-with-trulieve-to-launch-exclusively-in-arizona-at-harvest-dispensaries-301454080.html
Albert Einstone's LLC
Jan 05, 2022, 09:00 ET
LOS ANGELES, Jan. 5, 2022 /PRNewswire/ -- El Blunto, California's top blunt producer, announced their expansion into the Arizona market through a partnership with Trulieve Cannabis Corp., a leading and top-performing cannabis company in the United States. El Blunto products will be available during a two-week exclusive arrangement at all Trulieve-affiliated Harvest retail locations in Arizona beginning on Friday, January 7, 2022.
"At El Blunto, we pride ourselves in creating products for the cannabis connoisseur. We are beyond excited to expand our brand's accessibility and footprint on a national level. We made a conscious decision to kick off our national expansion in Arizona with Trulieve," said Q. Ladraa, CEO of Albert Einstone's, El Blunto's parent company. "Trulieve takes a meticulous approach to brand development and customer satisfaction, and we deeply identify with their ethos."
El Blunto will be available at all 17 Trulieve-affiliated Harvest retail locations in Arizona. The dispensary locations in Arizona include Avondale, Casa Grande, Chandler, Cottonwood, Glendale, Guadalupe, Lake Havasu, Mesa, Peoria, Phoenix, Scottsdale, Tempe and Tucson.
"Trulieve is excited to expand our product portfolio with the addition of El Blunto in the Arizona market," said Kim Rivers, CEO of Trulieve. "We strive to provide our patients and customers with access to superior products such as El Blunto that are sure to exceed their expectations."
El Blunto manufactures the highest quality pre-rolls in cannabis. Their products are available in 400+ dispensaries across California and now in all Trulieve locations across Arizona. Their signature product, The World's Finest Cannabis Cigar, is a tobacco free blunt that features 1.75 grams of top-shelf high-testing cannabis. Full flower is hand-broken, never ground, hand-rolled in an all-natural fiber wrap, cured for 72-hours, and finished with a glass filter.
About El Blunto
El Blunto is a California-based cannabis brand that offers 'The World's Finest Cannabis Experience'. Born from a passion for craftsmanship and quality, El Blunto is an evolution of historic cigar-making tradition. Borrowing age-old techniques from master cigar-rollers, we create products of the highest caliber with the highest level of finishing. Product design and development is approached like a true science, ensuring customers get the same, phenomenal experience every single time. The El Blunto line up includes El Blunto (cannabis cigar), El Bluntito (mini-blunts), El Jointo and El Jointito (joints and mini-joints), as well as pouches of full-flower and Roll Your Own Blunt Kits. El Blunto products are available in 400+ dispensaries across California and Arizona. El Blunto is a subsidiary of Albert Einstone's LLC.
For more information, visit www.alberteinstones.com
Follow us on instagram @Elblunto.ca @Alberteinstones
About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S. operating in 11 states, with leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com.
SOURCE Albert Einstone's LLC
2021 Year In Review --->>> https://www.indiva.com/press-releases/releases-2021/year-in-review-2021-highlights/
MediPharm Labs Completes Payment of All Convertible Debt
https://www.medipharmlabs.com/news/press-releases/detail/201/medipharm-labs-completes-payment-of-all-convertible-debt
January 05, 2022
TORONTO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce that it has completed all payments required under its 2020 $41 million unsecured convertible debt.
“MediPharm continues on its plan and path to profitability, and paying off our convertible debt in full is a major milestone on that path,” said Bryan Howcroft, CEO, MediPharm Labs. “Being essentially debt free with a strong cash position adds even more longevity to our business. As part of our growing nascent industry, this advantageous position differentiates us from some of our peers who may not have the runway to realize the industry’s full potential.”
On June 8, 2020, the Company closed a private placement with an US institutional investor for gross proceeds of $37.8 million through the issuance of two senior unsecured convertible notes. Starting in October 2020, the notes amortized through bi-monthly installment payments payable, in cash or shares, on the first and tenth business day of each month prior to the maturity date of June 8, 2023. During the interim period between payment dates, the holder of the notes had the option to convert accelerated installment amounts, in whole or in part at an installment conversion price calculated in accordance with the terms of the notes. As of December 31, 2021, the entire debt has been repaid in full through both cash installments and share accelerations. This extinguishes the debt in full 18 months before the maturity date.
MediPharm Labs has no other material debt and full ownership of its assets, which includes two GMP facilities – one in the province of Ontario, Canada and the other in the state of Victoria, Australia. Other major assets include manufacturing infrastructure and equipment.
The Company is now debt agreement free with a clean balance sheet and strong cash position. This position paired with a robust plan to reduce overhead, operating expenses and general and administrative expenses gives MediPharm Labs longevity to execute on its sales contracts and pipeline.
Cautionary Note Regarding Forward-Looking Information:
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, statements regarding: the Company’s plan and path to profitability; longevity; the industry’s potential; clean balance sheet; strong cash position; robust plan to reduce overhead, operating expenses and general and administrative expenses; and executing on sales contracts and pipeline. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs’ filings, available on the SEDAR website at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.
For further information, please contact:
MediPharm Labs Investor Relations
Telephone: +1 416.913.7425 ext. 1525
Email: investors@medipharmlabs.com
Website: www.medipharmlabs.com
Primary Logo
Source: MediPharm Labs Corp.
Released January 5, 2022
Almost dead --->>>Aleafia Health Skips Interest Payment As It Looks To Negotiate With Holders Of $37.4 Million In Outstanding Debt
January 4, 2022 8:47 AM
By: Jay Lutz
In a development that is perhaps surprising to absolutely no one, Aleafia Health (TSX: AH) announced this morning it is currently in negotiations with holders of its convertible debt. The debt comes due later this year, on June 27.
Originally issued in June 2019, the debt at issuance raised proceeds of $40.3 million from the company. Of that figure, just $2.9 million has been repaid, with a total outstanding principal amount now pegged at approximately $37.4 million as of September 30.
The firm however did secure a total of $19 million via a term loan and receivables facility just last week. With current cash on hand of just $4.7 million and a further $6.7 million in marketable securities and $8.2 million in trade receivables as of September 30, the firm has little chances of repaying the debt. And with a conversion price of $1.55 per share, there is little hope for the firm to see any further debt settled via equity conversion under the current terms.
In connection with these negotiations being underway, the company has not made an interest payment that was required to be made on December 31. This, however, is not classified as a default until thirty days after the payment is due.
The firm is currently looking to “achieve an outcome that is beneficial to all the Company’s stakeholders.” Notably, the debt is unsecured against the firms assets.
Aleafia Health last traded at $0.135 on the TSX.
MedMen Announces Termination of Investment Agreement
01/03/2022
https://investors.medmen.com/press-releases/press-release-details/2022/MedMen-Announces-Termination-of-Investment-Agreement/default.aspx
LOS ANGELES--(BUSINESS WIRE)-- MedMen Enterprises Inc. (“MedMen” or the “Company”) (CSE: MMEN) (OTCQX: MMNFF), a premier cannabis retailer with operations across the United States, today announced its termination of that certain Investment Agreement, dated as of February 25, 2021 (the “Investment Agreement”), by and among MedMen NY, Inc., a New York corporation, MM Enterprises USA, LLC, a Delaware limited liability company, AWH New York, LLC, a Delaware limited liability company, and Ascend Wellness Holdings, Inc. (“AWH”), a Delaware corporation. The Investment Agreement, pursuant to which AWH would have invested into MedMen’s New York Operations, was previously announced in a press release dated as of February 25, 2021.
ABOUT MEDMEN:
MedMen is a premier American cannabis retailer with an operational footprint in California, Nevada, Illinois, Arizona, Massachusetts, and Florida. MedMen offers a robust selection of high-quality products, including MedMen-owned brands MedMen Red and LuxLyte through its premium retail stores, proprietary delivery service, as well as curbside and in-store pickup. MedMen Buds, an industry-first loyalty program, provides exclusive access to promotions, product drops and content. MedMen believes that a world where cannabis is legal and regulated is safer, healthier, and happier. Learn more about MedMen at www.medmen.com.
Cautionary Note Regarding Forward-Looking Information and Statements:
This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only MedMen’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of MedMen’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “would have”. This forward-looking information is based on certain assumptions made by management and other factors used by management in developing such information. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and MedMen does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. Forward-looking statements contained in this news release are expressly qualified by this cautionary note.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220103005249/en/
MedMen Media Contact:
Lisa Weser
MedMen@Trailblaze.co
MedMen Investor Relations Contact:
Investors@MedMen.com
Source: MedMen Enterprises Inc.
Green Thumb Industries Announces Conference Participation for January 2022
JANUARY 3, 2022
https://investors.gtigrows.com/investors/news-and-events/press-releases/press-release-details/2022/Green-Thumb-Industries-Announces-Conference-Participation-for-January-2022/default.aspx
CHICAGO and VANCOUVER, British Columbia, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Green Thumb Industries Inc. (Green Thumb) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of RYTHM, Dogwalkers and incredibles branded cannabis products, today announced its executive team will participate in the following conferences in January 2022:
ICR Virtual Conference 2022, January 10-11, 2022: Founder and Chief Executive Officer Ben Kovler will participate in a panel and company presentation. Management will participate in one-on-one meetings.
24 th Annual Needham Virtual Growth Conference, January 14, 2022: Management will participate in one-on-one meetings.
About Green Thumb Industries:
Green Thumb Industries Inc. (“Green Thumb”), a national cannabis consumer packaged goods company and retailer, promotes well-being through the power of cannabis while giving back to the communities in which it serves. Green Thumb manufactures and distributes a portfolio of branded cannabis products including Beboe, Dogwalkers, Doctor Solomon’s, Good Green, incredibles and RYTHM. The company also owns and operates rapidly growing national retail cannabis stores called Rise. Headquartered in Chicago, Illinois, Green Thumb has 17 manufacturing facilities, 73 open retail locations and operations across 15 U.S. markets. Established in 2014, Green Thumb employs approximately 3,600 people and serves millions of patients and customers each year. The company was named to Crain’s Fast 50 list in 2021 and a Best Workplace by MG Retailer magazine in 2018, 2019 and 2021. More information is available at www.GTIgrows.com.